Bio Essence CORP

Bio Essence Corp. has finalized the acquisition of MediFlow AI software from Zhituo Software Co., Limited, through an asset purchase agreement valued at $3.5 million.

Bio Essence Corp. has determined that its financial statements for the quarter ending March 31, 2024, can no longer be relied upon due to an error in accounting for a lease termination.

Bio Essence Corp. has dismissed its previous independent accountant, Keith K. Zhen, CPA, and appointed Simon & Edward, LLP as its new principal accountant.

Bio Essence Corp. has dismissed its previous independent accountant, Keith K. Zhen, CPA, and appointed Simon & Edward, LLP as its new principal accountant, effective August 1, 2024.

Bio Essence Corp. has announced the resignation of two directors, the appointment of a new director, and the adoption of an insider trading policy.

Bio Essence Corp. has sold its wholly-owned subsidiary, Bio Essence Herbal Essentials, Inc., to Health Up, Inc. for $400,000 in cash.

Bio Essence Corp. reported a significant surge in revenue for the first quarter of 2026, driven by a substantial increase in OEM service orders.

Bio Essence Corp. reported significantly reduced net losses and a strategic pivot to OEM services, yet faces substantial doubt about its ability to continue as a going concern.

Bio Essence Corp. reports improved operational results in continuing segments but faces severe liquidity issues with zero cash and a going concern warning.

Bio Essence Corp. reports a net loss of $205,752 for Q1 2025 and acknowledges substantial doubt about its ability to continue as a going concern.

Bio Essence Corp. has filed an amendment to its Form 10-Q for the quarter ended June 30, 2024, to update disclosures regarding internal controls, while the rest of the report remains unchanged.

Bio Essence Corp. has filed an amended quarterly report to address internal control deficiencies and reflect the sale of two subsidiaries, impacting financial results for the period ending March 31, 2024.

Bio Essence Corp. reported a significant turnaround to net income in 2025, driven by a strategic shift to OEM services, despite ongoing litigation and internal control deficiencies.

Bio Essence Corp.'s 2024 10-K filing reveals increased net losses and a going concern uncertainty, despite revenue generation from continuing operations following subsidiary disposals.

Bio Essence Corp. reports a net loss of $971,879 for 2023, impacted by decreased sales and increased operating expenses, while also selling a subsidiary for $300,000.

Bio Essence Corp's CEO, Yin Yan, has sold a substantial amount of company stock over a three-day period.

Yin Yan, Director and CEO of Bio Essence Corp, files an amendment to Form 4 to correct a typographical error, clarifying her beneficial ownership as 14,000,000 shares of common stock.

Bio Essence Corp CEO Yin Yan reported selling shares of common stock in multiple transactions between September 25, 2024, and October 1, 2024.

Bio Essence Corp CEO Yin Yan reported selling a total of 223,965 shares of common stock between July 2nd and July 8th, 2024.

Bio Essence Corp CEO Yin Yan reported selling shares of common stock between July 2nd and July 8th, 2024.

Bio Essence Corp's CEO, Yin Yan, reports acquiring 5,000,000 shares of common stock at $0.50 per share and disposing of 19,000,000 shares.